Automate Your Wheel Strategy on BMEA
With Tiblio's Option Bot, you can configure your own wheel strategy including BMEA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMEA
- Rev/Share 0.0333
- Book/Share 0.7846
- PB 1.8991
- Debt/Equity 0.2758
- CurrentRatio 2.2549
- ROIC -3.62
- MktCap 55982578.0
- FreeCF/Share -3.1086
- PFCF -0.4917
- PE -0.5492
- Debt/Assets 0.144
- DivYield 0
- ROE -1.5273
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BMEA | Rodman & Renshaw | Neutral | Buy | -- | $18 | Sept. 27, 2024 |
| Upgrade | BMEA | Truist | Hold | Buy | -- | $54 | Sept. 27, 2024 |
| Initiation | BMEA | CapitalOne | -- | Overweight | -- | $25 | Aug. 29, 2024 |
News
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
BMEA
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will feature two oral presentations, one poster presentation, and chair a symposium at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025).
Read More
About Biomea Fusion, Inc. (BMEA)
- IPO Date 2021-04-16
- Website https://biomeafusion.com
- Industry Biotechnology
- CEO Dr. Michael J. M. Hitchcock Ph.D.
- Employees 79
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.